Jan. 14 at 12:45 PM
$XERS The story of Xeris is as follows:
A)Revenues:
Should approach
$400M this year, without new competition to Recorlev in the fast-growing cortisol-reduction market.
B)Gross margins: Around 85%!!
C)Profitability & self-sustainability:
The company is expected to turn profitable starting Q4 2025 and show growing profitability, becoming self-sustaining in 2026.
D)XP-8121:
Another blockbuster-potential, alongside Recorlev, with an estimated
$2-3B annual potential. Expected to enter Phase 3 in 2026 following excellent P2 results in both efficacy and safety. Notably, 72% of trial participants requested to continue treatment! Given the drug class (levo), its specialty profile, and the strong data, I believe there is over an 80% probability of commercialization by ~2029.
Overall, it is difficult to find another company with these fundamentals and strong blockbuster potential trading below a
$3B MC. That is the level I believe Xeris will surpass during 2026, based on fair expectations.
